Reliant AIGen AI-based data analytics software provider, announced a €10.1 million seed funding round to launch in stealth. The new capital was co-led by Tola Capital and Inovia Capital, with participation from angel investor Mike Volpi.
Reliant AI was founded by Karl Moritz Hermann, Marc Bellemare, and Richard Schlegel, natural language processing and reinforcement learning scientists and researchers who led teams at DeepMind, Google Brain, and EY Parthenon. They are passionate about how generative AI can solve information problems to reduce repetitive mental work and accelerate decision-making in businesses. The company is initially targeting the biopharmaceutical industry, and will use the new funding to hire engineering talent and expand its technology investments and presence in Europe and North America.
AI Products for Life Sciences
“Information and data are a severely overlooked part of advancing life sciences to create a better world. The sheer volume of manual labor involved in today’s data-intensive industries means that many highly skilled professionals are focused on manipulating data rather than solving complex problems. We’ve created an AI system that fundamentally advances our ability to conduct large-scale research by understanding life sciences.” Karl Moritz Hermann, CEO and co-founder of Reliant AI, said.
Reliant AI’s first product, Reliant Tabular, is an AI workbench that has attracted significant attention across key business segments in the biopharmaceutical industry. It helps life science analysts find scientific evidence for decision making through automated systematic review, asset scanning, comprehensive analytics, and a customizable data platform. With Reliant AI, you can query anything.
Reliant Tabular’s capabilities include proprietary ML models optimized for biopharmaceutical professionals, a comprehensive approach to fact discovery (maximizing recall so nothing is missed). It provides a user interface that allows you to quickly and easily adjust generated results and real-world evidence, and provides reports that allow your team to collaborate on analyses.
Opportunities in the Biopharmaceutical Industry
“The biopharmaceutical industry has a massive and scarce demand for information. Reliant AI combines cutting-edge research with domain expertise to create software that can clean up a day’s worth of data in 30 seconds. Marc, Karl Moritz, and the technology team bring together decades of AI expertise from the world’s leading research groups, including DeepMind, Google Brain, and Meta, giving Reliant the ability to truly move the needle in applying generative AI to difficult data problems.” Aaron Fleishman, partner at Tola Capital, said:
“We see significant market opportunity in the pharmaceutical sector as companies look to partner and build on new entrants to develop innovative solutions like those offered by Reliant AI.” Steve Woods, partner at Inovia Capital, added: “The significant demand in this large and growing market highlights the potential for AI to drive impactful advancements in the biopharmaceutical industry.”